Drug intelligence / Profile preview

technetium (99mTc) ethylenedicysteine (CIS bio international)

Development stage
Unknown
Lead developer
CISBIO
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Technetium (99mTc) ethylenedicysteine (also known as 99mTc-EC or 99mTc-LLEC) is a diagnostic radiopharmaceutical used as a renal tubular imaging agent in dynamic renal scintigraphy (renography). It is a hydrophilic technetium-99m complex of L,L-ethylenedicysteine (L,L-EC) that is rapidly cleared from the blood and excreted into the urine primarily via active renal tubular secretion, with minimal hepatobiliary excretion. It serves as a highly stable and effective alternative to technetium-99m mercaptoacetyltriglycine (99mTc-MAG3) and iodine-131 orthoiodohippurate (131I-OIH) for evaluating renal function, perfusion, and urinary tract obstruction, particularly in pediatric patients and those with unilateral or bilateral duplicated kidneys.

Brand names
Edicis
Other names
99mTc-EC99mTc-L,L-EC99mTc-LLEC99mTc-ethylenedicysteinetechnetium (99mTc) L,L-ethylenedicysteinetechnetium Tc 99m L,L-ethylenedicysteinetechnetium Tc 99m ethylenedicysteine
02

Targets

OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)

Beyond the preview

Go deeper on technetium (99mTc) ethylenedicysteine (CIS bio international).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium (99mTc) ethylenedicysteine (CIS bio international).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call